专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-6693122-B2 优先权日:1999-05-12 标题:Nitrosated and nitrosylated potassium channel activators, compositions and methods of use 发明人:GARVEY DAVID S; SAENZ DE TEJADA INIGO 权利人:NITROMED INC 摘要:The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.
专利号:US-2014315720-A1 优先权日:2012-10-24 标 题 :Polysaccharide ester microspheres and methods and articles relating thereto 发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY 权利人:CELANESE ACETATE LLC 摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
专利号:CN-108569987-A 优先权日:2017-03-10 标题:A kind of synthesis technology of intermediate
1: Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med. 2011 Jan-Feb;24(1):86-92. doi: 10.3122/jabfm.2011.01.080096. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. doi: 10.3122/jabfm.2011.01.080096. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review. Review.
合成参考文献
参考文献:10.1007/bf02253566|10.1159/000025393 摘要:Lai L, Su M, Tseng Y, Lien W. Sensitivity of the Slow Component of the Delayed Rectifier Potassium Current (IKs) to Potassium Channel Blockers: Implications for Clinical Reverse Use-Dependent Effects. Journal of Biomedical Science. 1999 Jul 16;6(4):251–9. doi: 10.1159/000025393. 参考文献:10.1007/s11936-001-0028-3 摘要:Balaji S. Postoperative cardiac arrhythmias in children. Current Treatment Options in Cardiovascular Medicine. 2001 Oct;3(5):385–92. doi: 10.1007/s11936-001-0028-3. 参考文献:10.1007/s00380-003-0750-8 摘要:Hiramatsu M, Wu LM, Hirano Y, Kawano S, Furukawa T, Hiraoka M. Block of HERG current expressed in HEK293 cells by the Na+-channel blocker cibenzoline. Heart Vessels. 2004 May;19(3):137–43. doi: 10.1007/s00380-003-0750-8. 参考文献:10.1007/s00508-008-0940-6 摘要:Altmann D, Eggmann U, Ammann P. [Drug induced QT prolongation]. Wien Klin Wochenschr. 2008;120(5-6):128–35. doi: 10.1007/s00508-008-0940-6. 参考文献:10.2165/00003495-200868050-00004 摘要:Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs. 2008;68(5):607–30. doi: 10.2165/00003495-200868050-00004.